News

HDA UK Media And Political Bulletin – 14 December 2017

Media and Political Bulletin

14 December 2017

The BBC Radio 4 consumer affairs progamme ‘You and Yours’, reported on the current drugs shortages in the UK yesterday, the programme asked the HDA for comment and the association provided a statement. To listen to the coverage of drugs shortages on the programme, please click here. The clip starts at 34 minutes.

Media Summary

EU and UK life sciences industry issue joint policy document on Brexit

ABPI, 14 December 2017

 

The ABPI reports that eleven associations representing the European and British life science industry, including the ABPI, have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union. Setting out their priorities in advance of the European Council taking place on 14-15 December in Brussels, the sector has sent a clear message that the regulation, trade and supply of medicines must be a priority for the second phase of negotiations.

Among several key priorities, the joint paper sets out the following:

  • Patient access to medicines must be a primary consideration for phase two of the Article 50 negotiations.
  • Close cooperation in the regulation of medicines, including mutual recognition of regulatory activities and quality testing, is essential in ensuring that patients in the EU and the UK can continue to access medicines.
  • Trade between the UK and EU will ensure that medicines are able to continue to move between both regions, ensuring that both UK and EU patients can continue to access medicines.
  • Provided the UK remains in the single market or in a new legal arrangement with the EU based on consistency of regulatory frameworks, the EU and the UK IP systems should remain aligned in order to avoid uncertainties for industry.

 

Parliamentary Coverage

House of Commons – Tabled Written question – Department of Health, 13 December 2017

Ronnie Cowan MP: To ask the Secretary of State for Health, what discussions his Department has had on ensuring that decisions on the timetable for UK drug licensing remain linked to the timetable for decisions to be made the European Medicines Agency after the UK leaves the EU.

Full Coverage

EU and UK life sciences industry issue joint policy document on Brexit

ABPI, 14 December 2017

 

Eleven associations representing the European and British life science industry, including the Association of the British Pharmaceutical Industry (ABPI), have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union.

Today, the Association of the European Self-Medication Industry (AESGP), the ABPI, the BioIndustry Association (BIA), the British Generics Manufacturers Association (BGMA), European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the European Association for Bioindustries (EuropaBio), Medicines for Europe, the Proprietary Association of Great Britain (PAGB) and Vaccines Europe, have called for medicines to be a priority in phase two of the Article 50 negotiations.

Setting out their priorities in advance of the European Council taking place on 14-15 December in Brussels, the sector has sent a clear message that the regulation, trade and supply of medicines must be a priority for the second phase of negotiations.

Whilst being encouraged by the breakthrough in phase one of the negotiations so that the second phase can now begin, the sector states that focusing on the framework for transitional arrangements and future relations with the UK must be a priority for negotiators.

The organisations are of the opinion that the agreement of transitional arrangements after March 2019 will be critical in ensuring there is minimal disruption to patients receiving medicines after the UK leaves the EU. Such a period will be essential in allowing companies to make the necessary changes to marketing authorisations and to their supply chains and ensure patients experience no disruption to their access to medicines. As such, negotiators should include access to medicines and the implications of Brexit for patients across the EU in the second phase of negotiations and be agreed in both the future agreement and in transitional arrangements.

The publication of this joint policy paper shows that the integrated nature of the supply chains for medicines across Europe, alongside a shared regulatory framework, means that patients in both the UK and EU need an early agreement on the future of medicines in phase second of the negotiations.

Among several key priorities, the joint paper sets out the following:

Patient access to medicines must be a primary consideration for phase two of the Article 50 negotiations.

Close cooperation in the regulation of medicines, including mutual recognition of regulatory activities and quality testing, is essential in ensuring that patients in the EU and the UK can continue to access medicines.

Trade between the UK and EU will ensure that medicines are able to continue to move between both regions, ensuring that both UK and EU patients can continue to access medicines.

Provided the UK remains in the single market or in a new legal arrangement with the EU based on consistency of regulatory frameworks, the EU and the UK IP systems should remain aligned in order to avoid uncertainties for industry.

HDA UK Media And Political Bulletin – 14 December 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?